Antonio Fernandez Santidrian - 17 Aug 2026 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Chief Scientific Officer
Issuer ticker: CLDI
Reported as of: 17 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Aug 2026, 19:00:05 UTC
Prior SEC filing: 05 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Antonio Fernandez Santidrian

Key filing fact

Antonio Fernandez Santidrian filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 19 Aug 2026.

Key facts

This page summarizes Antonio Fernandez Santidrian's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2026, 19:00.

Change

Previous filing in this sequence was filed on 05 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001990403 Primary reporting owner

Fernandez Santidrian Antonio

Relationship: Chief Scientific Officer
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Antonio Fernandez Santidrian
Signature date: 19 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDI transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +16,000
Change %
Price
Shares after: 16,000
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 16,000
Exercise price: $1.36
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 16,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.

Footnote F2

Does not include the incentive stock options previously granted to the Reporting Person.

SEC remarks

Exhibit 24 - Power of Attorney